Octarine Bio, the synthetic biology drug development company that produces psilocybin from sugar using fermentation, partners with clinical research organisation Clerkenwell Health to deliver clinical trials. Europe’s commercial psychedelic healthcare ecosystem is growing, building on a strong heritage of academic and civil society support A partnership between two innovative startups leads the…


Previous articleGlutamate’s Role in Rapidly-Acting Antidepressants
Next articlePharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021